

- Wild type MIC (and zone diameter) distributions
 - ECOFFs (vs. clinical breakpoints)
- The EUCAST international MIC distribution database

Gunnar Kahlmeter

EUCAST

Växjö, Sweden

The MIC is a relative value and will vary with the "system"

- Medium
- pH
- Cation concentration
- Inoculum
- Atmosphere
- Growth characteristics and ability
- Incubation time
-

INTERNATIONAL
STANDARD

ISO
20776-1

Second edition
2019-06

We go to great lengths to achieve reproducibility – but the MIC value is still only a relative value.

Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices —

Part 1:


Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases

If

- you stick to the methodology,
 - buy the best material,
 - educate and train yourself and staff,
 - avoid common pitfalls and
 - practice, practice, practice
- the testing of one and the same isolate and the testing of many isolates will generate MIC distributions like these:


MIC – reproducibility of the MIC and defining a wild type

Repeat MIC testing of one strain (one lab, reference BMD)




MIC – reproducibility of the MIC and defining a wild type

MIC testing of consecutive clinical isolates (one lab, reference BMD)



MIC – reproducibility of the MIC and defining a wild type

MIC testing of clinical isolates,
many investigators.




MIC – reproducibility of the MIC and defining a wild type

Repeat MIC testing of one strain
(one lab, reference BMD)

MIC testing of consecutive clinical
isolates (one lab, reference BMD)

MIC testing of clinical isolates,
many investigators.



For >20 years EUCAST has systematically gathered MIC (and zone diameter) distributions and made them publicly and freely available

<https://mic.eucast.org>

The screenshot shows the EUCAST website interface. At the top, there is a navigation bar with links for Home, Contact, Sitemap, and Newsletter, along with social media icons for Facebook, Twitter, LinkedIn, and YouTube. The main header features the EUCAST logo and the text "EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING" and "European Society of Clinical Microbiology and Infectious Diseases". A search bar is located on the right side of the header.

The main content area is titled "MIC and zone distributions and ECOFFs". On the left, there is a sidebar menu with various categories, including "Organization", "Consultations", "EUCAST News", "New definitions of S, I and R", "Clinical breakpoints and dosing", "Rapid AST in blood cultures", "Expert rules and intrinsic resistance", "Resistance mechanisms", "SOPs and Guidance documents", "MIC and zone distributions and ECOFFs", "AST of bacteria", "AST of mycobacteria", "AST of fungi", and "AST of veterinary pathogens". A yellow arrow points to the "MIC and zone distributions and ECOFFs" category in the sidebar.

The main content area displays a bar chart titled "E.coli with cefotaxime 5 ug 112 non-consecutive isolates chose because of resistance". The chart shows the number of isolates (Y-axis, 0 to 18) versus the inhibition zone diameter in mm (X-axis, 0 to 28). The legend indicates the MIC values for each bar: 512, 32, 16, 8, 4, 2, 1, 0.5, 0.25, and 0.125. The chart shows a distribution of inhibition zone diameters, with a peak around 10-12 mm and a tail extending to 28 mm.

Below the chart, there is a dropdown menu labeled "MIC and zone distributions and ECOFF" with a downward arrow. The main content area is titled "MIC and zone diameter distributions and ECOFFs".

1. Distributions and ECOFFs

2. MIC and zone diameter correlations

The EUCAST software, originally created in 2003, for displaying distributions of MIC-values (generated with methods calibrated to broth microdilution or agar dilution) and inhibition zone diameters (generated with EUCAST disk diffusion methodology) was re-programmed during 2020 and re-launched on 24 November, 2020. Each graph is shown in two versions where one is constructed by adding all approved distributions and the other by adding weighted distributions. The later is generated through converting numbers to per cent before adding individual distributions. This prevents large distributions from dominating or even "obliterating" smaller distributions and allows all distributions equal weight. During 2021 distributions are curated in accordance with EUCAST SOP10.1 and all values gradually reviewed.

EUCAST open website for MIC and Zone diameter distributions and ECOFFs was created (<https://mic.eucast.org>)

☰

MIC EUCAST Login

Antimicrobial wild type distributions of microorganisms

Mic distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance

[Search database](#)



MIC and Inhibition zone diameter distributions of microorganisms without and with phenotypically evident resistance mechanisms

MIC and inhibition zone diameter distributions

The database of MIC and zone diameter distributions was created by Gunnar Kahlmeter for EUCAST from 2002 and onwards. More data is regularly added and all data is curated by Gunnar Kahlmeter and John Turnidge, EUCAST. Distributions are shown as "aggregated distributions" and as "aggregated weighted distributions". For aggregated distributions all accepted distributions (as defined in SOP 10) were added to form one common distribution. For aggregated weighted distributions each individual distribution was converted to contribute equally to the common aggregated distribution. In this way large distributions are prevented from drowning out smaller distributions.

For additional information on "Wild type distributions and ECOFFs" see Gunnar Kahlmeter & John Turnidge. How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff values. *Clinical Microbiology and Infection* 2022 Jul;28(7):952-954. DOI: [10.1016/j.cmi.2022.02.024](https://doi.org/10.1016/j.cmi.2022.02.024)

Gunnar Kahlmeter & John Turnidge. Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utility. *Clinical Microbiology Reviews* 2023. DOI: [10.1128/cmr.00100-22](https://doi.org/10.1128/cmr.00100-22)



Antimicrobial wild type distributions of microorganisms

Mic distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance

Search database

Method

MIC Disk diffusion

Antimicrobial

Cefotaxime

Species



Species...







Elements per page 50

MIC distributions for Cefotaxime, 2024-09-01

Antimicrobial: Cefotaxime (Method: MIC)

| | 0.002 | 0.004 | 0.008 | 0.016 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | Distributions | Observations | (T)ECOFF | Confidence interval |
|--|-------|-------|-------|-------|------|------|-------|------|-----|-----|-----|----|-----|-----|-----|-----|-----|-----|-----|---------------|--------------|----------|---------------------|
| <i>Acinetobacter baumannii</i> | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 24 | 4 | 7 | 20 | 72 | 289 | 338 | 127 | 55 | 6 | 88 | 5 | 6 | 1036 | 64 | 16 - 512 |
| <i>Citrobacter freundii</i> | 0 | 0 | 0 | 1 | 3 | 6 | 47 | 6 | 6 | 3 | 4 | 5 | 3 | 21 | 21 | 7 | 1 | 0 | 0 | 4 | 134 | (0.5) | 0.06 - 2 |
| <i>Citrobacter koseri</i> | 0 | 0 | 0 | 0 | 3 | 4 | 3 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 16 | ID | |
| <i>Clostridioides difficile</i> | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 30 | 139 | 47 | 24 | 1 | 243 | ID | |
| <i>Corynebacterium diphtheriae</i> | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 31 | 166 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 200 | ID | |
| <i>Corynebacterium ulcerans</i> | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 175 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 200 | ID | |
| <i>Enterobacter agglomerans</i> | 0 | 0 | 0 | 2 | 4 | 27 | 17 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 54 | ID | |
| <i>Enterobacter cloacae</i> | 1 | 2 | 10 | 43 | 137 | 222 | 386 | 341 | 222 | 83 | 54 | 54 | 68 | 101 | 162 | 169 | 78 | 76 | 23 | 28 | 2232 | 1 | 0.25 - 2 |
| <i>Escherichia coli</i> | 0 | 5 | 37 | 303 | 1618 | 4952 | 2362 | 470 | 189 | 80 | 49 | 47 | 38 | 52 | 71 | 131 | 24 | 31 | 28 | 44 | 10487 | 0.25 | 0.125 - 0.25 |
| <i>Escherichia coli</i> ATCC 25922 | 0 | 0 | 0 | 0 | 0 | 33 | 67 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 100 | ID | |
| <i>Escherichia coli</i> NCTC 13846 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 67 | ID | |
| <i>Francisella tularensis</i> | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 3 | 11 | 5 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 32 | - | |
| <i>Haemophilus influenzae</i> | 42 | 339 | 3226 | 5616 | 2338 | 752 | 136 | 31 | 25 | 12 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 12518 | 0.06 | 0.016 - 0.125 |
| <i>Haemophilus influenzae</i> ATCC 49247 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 78 | ID | |
| <i>Kingella kingae</i> | 0 | 0 | 0 | 53 | 143 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 202 | ID | |





Wild type distributions are stereotype in appearance!

Commonly asked questions:

How are ECOFFs determined and who decides?

What is the relationship between ECOFFs and clinical breakpoints?

How often are clinical breakpoints and ECOFFs the same?


How ECOFFs are determined

- ECOFF requires five acceptable distributions
- TECOFF requires three acceptable distributions
- In the beginning ECOFFs were set using the "Eye-ball method"
- Later a statistical program (ECOFFinder) to assist was created (J Turnidge).

- Today ECOFFs are
 - Set jointly by the curators of the database
 - Statistical analysis AND a visual inspection
 - Regular review and revision (when data is added)
 - Open invitation for colleagues to (a) submit distributions and (b) be part of the ECOFF setting process and (c) to question the correctness of an ECOFF.

Cefotaxime / Escherichia coli
International MIC distribution - Reference database 2023-03-20
Based on aggregated distributions

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



MIC
Epidemiological cut-off (ECOFF): 0.25 mg/L
Wildtype (WT) organisms: ≤ 0.25 mg/L

Confidence interval: 0.125 - 0.25
10487 observations (44 data sources)

| 0,002 | 0,004 | 0,008 | 0,016 | 0,032 | 0,064 | 0,12 | 0,25 | 0,5 | 1 | 2 | 4 | 8 | 126 | 32 | 64 | 128 | 256 |
|-------|-------|-------|-------|-------|-------|------|------|-----|----|---|----|---|-----|----|----|-----|-----|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1671 | 205 | 20 | 6 | 2 | 0 | 0 | 1 | 17 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 4 | 16 | 10 | 4 | 0 | 6 | 1 | 2 | 3 | 0 | 0 | 0 | 0 |
| 0 | 0 | 3 | 1 | 28 | 51 | 9 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 4 | 7 | 47 | 310 | 510 | 99 | 12 | 5 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 20 | 97 | 185 | 116 | 31 | 33 | 6 | 5 | 3 | 7 | 1 | 42 | 23 | 7 | 0 |
| 0 | 0 | 0 | 0 | 28 | 108 | 88 | 13 | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 1 | 8 | 60 | 105 | 58 | 19 | 5 | 8 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 135 | 37 | 12 | 5 | 5 | 3 | 8 | 3 | 11 | 8 | 14 | 32 | 116 |
| 0 | 0 | 0 | 0 | 0 | 28 | 41 | 7 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 8 | 149 | 113 | 25 | 2 | 0 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 24 | 181 | 102 | 9 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 301 | 12 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 150 | 2 | 1 | 1 | 2 | 2 | 2 | 4 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 159 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 263 | 8 | 0 | 0 | 6 | 3 | 4 | 3 | 13 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 15 | 188 | 90 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 29 | 206 | 73 | 7 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 313 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 294 | 5 | 2 | 2 | 2 | 2 | 2 | 4 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 311 | 3 | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 292 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 49 | 82 | 85 | 12 | 4 | 2 | 0 | 2 | 1 | 5 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 593 | 23 | 4 | 8 | 5 | 6 | 2 | 2 | 1 | 0 | 0 | 0 |
| 0 | 0 | 1 | 4 | 39 | 135 | 38 | 4 | 4 | 1 | 2 | 0 | 3 | 6 | 3 | 1 | 0 | 3 |
| 0 | 0 | 0 | 17 | 97 | 558 | 251 | 42 | 11 | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| 0 | 0 | 0 | 19 | 86 | 408 | 390 | 49 | 12 | 3 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 2 |
| 0 | 0 | 3 | 42 | 200 | 514 | 49 | 14 | 1 | 4 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 2 | 1 | 11 | 57 | 25 | 17 | 4 | 6 | 1 | 4 | 1 | 2 | 1 | 1 | 0 | 0 |
| 0 | 0 | 1 | 1 | 14 | 41 | 36 | 9 | 2 | 2 | 5 | 1 | 0 | 1 | 0 | 3 | 0 | 1 |
| 0 | 0 | 1 | 3 | 27 | 48 | 22 | 4 | 4 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 3 | 7 | 2 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 2 | 10 | 13 | 1 | 0 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 0 | 1 | 0 | 1 | 25 | 81 | 8 | 5 | 2 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 5 |
| 0 | 0 | 0 | 2 | 19 | 19 | 60 | 20 | 5 | 4 | 3 | 1 | 1 | 3 | 1 | 0 | 1 | 7 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 0 | 5 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 4 | 3 | 18 | 20 | 4 | 5 | 6 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 9 | 10 | 8 | 2 | 3 | 4 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 1 | 0 | 18 | 24 | 10 | 3 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 1 | 2 | 17 | 5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 8 | 19 | 9 | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 13 | 13 | 10 | 6 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 1 | 7 | 18 | 17 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 1 | 0 | 7 | 16 | 9 | 8 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| 0 | 0 | 0 | 0 | 12 | 11 | 2 | 7 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 4 | 20 | 9 | 6 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 3 | 9 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| 0 | 0 | 0 | 0 | 4 | 5 | 1 | 1 | 0 | 1 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 17 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 28 | 8 | 4 | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 4 | 16 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 7 | 20 | 4 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 17 | 0 | 48 | 29 | 6 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| 0 | 0 | 0 | 17 | 0 | 61 | 22 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 0 | 1 | 0 | 4 | 52 | 24 | 9 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 0 | 0 | 2 | 0 | 12 | 43 | 16 | 4 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| 0 | 0 | 0 | 2 | 4 | 2 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 4 | 12 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 5 | 0 | 13 | 5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 7 | 0 | 14 | 7 | 0 | 3 | 0 | 1 | 0 | 1 | 3 | 0 | 2 | 0 | 2 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 3 | 5 | 62 | 113 | 25 | 8 | 3 | 1 | 0 | 3 | 3 | 5 | 1 | 0 | 1 | 3 |
| 0 | 0 | 0 | 3 | 18 | 105 | 71 | 12 | 4 | 0 | 1 | 0 | 1 | 7 | 4 | 0 | 8 | 3 |

Some MIC distributions are not accepted?

This table consists of 72 MIC distributions for cefotaxime on *E. coli*.

**31 were rejected.
41 were accepted.**

| 0,002 | 0,004 | 0,008 | 0,016 | 0,032 | 0,064 | 0,12 | 0,25 | 0,5 | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 |
|-------|-------|-------|-------|-------|-------|------|------|-----|----|---|----|---|----|----|----|-----|-----|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1671 | 205 | 20 | 6 | 2 | 0 | 0 | 1 | 17 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 4 | 16 | 10 | 4 | 0 | 6 | 1 | 2 | 3 | 0 | 0 | 0 | 0 |
| 0 | 0 | 3 | 1 | 28 | 51 | 9 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 4 | 7 | 47 | 310 | 510 | 99 | 12 | 5 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 20 | 97 | 185 | 116 | 31 | 33 | 6 | 5 | 3 | 7 | 1 | 42 | 23 | 7 | 0 |
| 0 | 0 | 0 | 0 | 28 | 108 | 88 | 13 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 1 | 8 | 60 | 105 | 58 | 19 | 5 | 8 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 135 | 37 | 12 | 5 | 5 | 3 | 8 | 3 | 11 | 8 | 14 | 32 | 116 |
| 0 | 0 | 0 | 0 | 0 | 28 | 41 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 8 | 149 | 113 | 25 | 2 | 0 | 1 | 3 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 24 | 181 | 102 | 9 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 301 | 12 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 150 | 2 | 1 | 1 | 2 | 2 | 2 | 4 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 159 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 263 | 8 | 0 | 0 | 6 | 3 | 4 | 3 | 13 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 15 | 188 | 90 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 29 | 206 | 73 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 313 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 294 | 5 | 2 | 2 | 2 | 2 | 2 | 4 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 311 | 3 | 0 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 292 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 49 | 82 | 85 | 12 | 4 | 2 | 0 | 2 | 1 | 5 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 593 | 23 | 4 | 8 | 5 | 6 | 2 | 2 | 1 | 0 | 0 | 0 |
| 0 | 0 | 1 | 4 | 39 | 135 | 38 | 4 | 4 | 1 | 2 | 0 | 3 | 6 | 3 | 1 | 0 | 3 |
| 0 | 0 | 0 | 17 | 97 | 558 | 251 | 42 | 11 | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| 0 | 0 | 0 | 19 | 86 | 408 | 390 | 49 | 12 | 3 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 2 |
| 0 | 0 | 3 | 42 | 200 | 514 | 49 | 14 | 1 | 4 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 2 | 1 | 11 | 57 | 25 | 17 | 4 | 6 | 1 | 4 | 1 | 2 | 1 | 1 | 0 | 0 |
| 0 | 0 | 1 | 1 | 14 | 41 | 36 | 9 | 2 | 2 | 5 | 1 | 0 | 1 | 0 | 3 | 0 | 1 |
| 0 | 0 | 1 | 3 | 27 | 48 | 22 | 4 | 4 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 3 | 7 | 2 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 2 | 10 | 13 | 1 | 0 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 0 | 1 | 0 | 1 | 25 | 81 | 8 | 5 | 2 | 0 | 2 | 1 | 0 | 1 | 1 | 0 | 5 |
| 0 | 0 | 0 | 2 | 19 | 19 | 60 | 20 | 5 | 4 | 3 | 1 | 1 | 3 | 1 | 0 | 1 | 7 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 0 | 5 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 4 | 3 | 18 | 20 | 4 | 5 | 6 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 9 | 10 | 8 | 2 | 3 | 4 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 1 | 0 | 18 | 24 | 10 | 3 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 1 | 2 | 17 | 5 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 8 | 19 | 9 | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 13 | 13 | 10 | 6 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 1 | 7 | 18 | 17 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 1 | 0 | 7 | 16 | 9 | 8 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| 0 | 0 | 0 | 0 | 12 | 11 | 2 | 7 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 4 | 20 | 9 | 6 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 3 | 9 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| 0 | 0 | 0 | 0 | 4 | 5 | 1 | 1 | 0 | 1 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 17 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 28 | 8 | 4 | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 4 | 16 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 7 | 20 | 4 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 17 | 0 | 48 | 29 | 6 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| 0 | 0 | 0 | 17 | 0 | 61 | 22 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 0 | 0 | 1 | 0 | 4 | 52 | 24 | 9 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 0 | 0 | 2 | 0 | 12 | 43 | 16 | 4 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 2 |
| 0 | 0 | 0 | 2 | 4 | 2 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 4 | 12 | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 5 | 0 | 13 | 5 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 7 | 0 | 14 | 7 | 0 | 3 | 0 | 1 | 0 | 1 | 3 | 0 | 2 | 0 | 2 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 3 | 5 | 62 | 113 | 25 | 8 | 3 | 1 | 0 | 3 | 3 | 5 | 1 | 0 | 1 | 3 |
| 0 | 0 | 0 | 3 | 18 | 105 | 71 | 12 | 4 | 0 | 1 | 0 | 1 | 7 | 4 | 0 | 8 | 3 |

Taking the rules to the cefotaxime distributions?

Excluded distributions are marked grey.

Accepted distributions:

AST method accepted

Full concentration series – no truncation

Sufficient number of isolates to permit identification of WT

Data to permit ECOFF calculation of individual distributions


ECOFF – the mean of ECOFFs of 5 or more accepted distributions.

Cefotaxime / Escherichia coli

International MIC distribution - Reference database 2023-03-20

Based on aggregated distributions

MIC distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance




MIC
Epidemiological cut-off (ECOFF): 0.25 mg/L
Wildtype (WT) organisms: ≤ 0.25 mg/L

Confidence interval: 0.125 - 0.25
10487 observations (44 data sources)

Checking the validity of MIC ECOFFs using zone diameter distributions.


Cefotaxime 5 µg vs. MIC
***E. coli*, 288 isolates (319 correlates)**



| Breakpoints | | ECOFF |
|---------------|-------------------|-----------|
| MIC | S ≤ 1, R > 2 mg/L | 0.25 mg/L |
| Zone diameter | S ≥ 20, R < 17 mm | |

Cefotaxime / Escherichia coli
International zone diameter distribution - Reference database 2024-09-01
EUCAST disk diffusion method
Based on aggregated distributions

Distributions include collated data from multiple sources, geographical areas and time periods and can never be used to infer rates of resistance



Disk content: 5
Epidemiological cut-off (ECOFF): 22 mm
Wildtype (WT) organisms: ≥ 22 mm

Confidence interval: 22 - 22
118213 observations (15 data sources)

Commonly asked questions:

How are ECOFFs determined and who decides?

What is the relationship between ECOFFs and clinical breakpoints?

How often are clinical breakpoints and ECOFFs the same?

ECOFFs and Clinical breakpoints

- There is no automatic relationship between the ECOFF and a clinical breakpoint
 - The clinical breakpoint can be the same, higher than or below the ECOFF
 - Benzylpenicillin and *Streptococcus pneumoniae* – higher
 - Vancomycin and *Staphylococcus aureus* - the same
 - Gentamicin and Enterococcus species (wild type isolates R)
- Clinical breakpoints should not divide wild type distributions
 - It does not make biological sense since the MIC distribution primarily represents technical variation
 - It will not permit good reproducibility of results in the wild type

Commonly asked questions:

How are ECOFFs determined and who decides?

What is the relationship between ECOFFs and clinical breakpoints?

How often are clinical breakpoints and ECOFFs the same?

Clinical breakpoints = ECOFFs

| Species | Agent | ECOFF | Breakpoint |
|-------------------------|--------------------------------------|-------------|------------|
| <i>Enterobacterales</i> | Ampicillin, amoxicillin +/-inhibitor | 8 | 8/8 |
| | Piperacillin +/-inhibitor | 8 | 8/8 |
| | Cefadroxil, cefalexin | 16 | 16/16 |
| | Ciprofloxacin | 0.12 - 0.25 | 0.25/0.5 |
| | Gentamicin, tobramycin, netilmicin | 2 | 2/2 |
| | Amikacin | 8 | 8/16 |
| | Tigecycline | 0.5 - 1 | 0.5/0.5 |
| | Colistin | 2 | 2/2 |
| | Fosfomycin (E. coli) | 8 | 4/4 |
| | Nitrofurantoin (E. coli) | 64 | 64/64 |
| | Nitroxoline | 16 | 16/16 |

Clinical breakpoints = ECOFFs

| Species | Agent | ECOFF | Breakpoint |
|-----------------------|------------------------------------|----------|----------------|
| <i>Ps. aeruginosa</i> | Piperacillintazobactam | 16 | 0.001/16 |
| | Cefepime | 8 | 0.001/8 |
| | Ceftazidime, Ceftazidime-avibactam | 8 (8) | 0.001/8 8/8 |
| | Ceftolozane-tazobactam | 4 | 4/4 |
| | Ciprofloxacin | 0.5 | 0.001/0.5 |
| | Meropenem | 2 | 2/8 |
| | Gentamicin Tobramycin | 8 2 | - 2/2 |
| | Colistin | 4 | 4/4 |

Clinical breakpoints = ECOFFs

| Species | Agent | ECOFF | Breakpoint |
|------------------------------|-------------------------|---------------|------------|
| <i>Staphylococcus aureus</i> | Benzylopenicillin | 0.12 or 0.064 | 0.12/0.12 |
| | Ciprofloxacin | 1 | 0.001/1 |
| | Moxifloxacin | 0.25 | 0.25/0.25 |
| | Amikacin, | 16 | 16/16 |
| | Gentamicin, tobramycin | 2 | 2/2 |
| | Vancomycin | 2 | 2/2 |
| | Macrolides | 1 | 1/2 |
| | Tetracycline | 1 | 1/2 |
| | Linezolid | 4 | 4/4 |
| | Tedizolid | 0.5 | 0.5/0.5 |
| | Chloramphenicol | 8 | 8/8 |
| | Daptomycin | 1 | 1/1 |
| | Nitrofurantoin | 64 | 64/64 |
| | Rifampicin | 0.06 | 0.06/0.06 |
| | Trimethoprim, Trimsulfa | | 2/4 |

Clinical breakpoints > ECOFFs

| Species | Agent | ECOFF | Breakpoint |
|-------------------------|-----------------------|---------|------------|
| <i>Enterobacterales</i> | Pivmecillinam | 1 | 8/8 |
| | Cefotaxime | 0.25 | 1/2 |
| | Ceftriaxone | 0.12 | 1/ 2 |
| | Ceftazidime | 0.5 | 1/4 |
| | Ceftazidime-avibactam | 0.5 | 8/8 |
| | Cefepime | 0.12 | 1/4 |
| | Imipenem | 0.5 - 1 | 2/4 |
| | Meropenem | 0.12 | 2/8 |
| <i>Ps. aeruginosa</i> | -- | -- | -- |
| <i>Staphylococcus</i> | Ceftaroline, general | 0.5 | 1 / 1 |
| | Ceftobiprole | 1 | 2 / 2 |

Beta-lactam agents hav low toxicity and a wide dose span

More information on wild type distributions and ECOFFs

- <https://mic.eucast.org>
- EUCAST SOP10.2

> [Clin Microbiol Infect.](#) 2006 Jun;12(6):501-3. doi: 10.1111/j.1469-0691.2006.01454.x.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing

G Kahlmeter ¹, D F J Brown, F W Goldstein, A P MacGowan, J W Mouton, I Odenholt, A Rodloff, C-J Soussy, M Steinbakk, F Soriano, O Stetsiouk

> [Antimicrob Agents Chemother.](#) 2009 Apr;53(4):1628-9. doi: 10.1128/AAC.01624-08.
Epub 2009 Feb 2.

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species

Maiken Cavling Arendrup ¹, Gunnar Kahlmeter, Juan Luis Rodriguez-Tudela, J Peter Donnelly

[Review](#) > [Clin Microbiol Rev.](#) 2023 Dec 20;36(4):e0010022. doi: 10.1128/cmr.00100-22.
Epub 2023 Dec 1.

Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utility


Gunnar Kahlmeter ^{1 2 3}, John Turnidge ^{4 5}

Affiliations + expand

PMID: 38038445 PMCID: PMC10732016 DOI: 10.1128/cmr.00100-22

Free PMC article

FULL TEXT LINKS



ACTIONS



SHARE

Turnidge J. • Kahlmeter G. • Kronvall G.

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

Clin Microbiol Infect. 2006; **12**: 418-425

[Review](#) > [J Antimicrob Chemother.](#) 2015 Sep;70(9):2427-39. doi: 10.1093/jac/dkv145.

Epub 2015 Jun 18.

The 2014 Garrod Lecture: EUCAST – are we heading towards international agreement?

Gunnar Kahlmeter ¹

Affiliations + expand

PMID: 26089441 DOI: 10.1093/jac/dkv145

[Review](#) > [Clin Microbiol Infect.](#) 2022 Jul;28(7):952-954. doi: 10.1016/j.cmi.2022.02.024.

Epub 2022 Feb 24.

How to: ECOFFs—the why, the how, and the don'ts of EUCAST epidemiological cutoff values

Gunnar Kahlmeter ¹, John Turnidge ²

Review

> [Clin Microbiol Rev.](#) 2023 Dec 20;36(4):e0010022. doi: 10.1128/cmr.00100-22.

Epub 2023 Dec 1.

Wild-type distributions of minimum inhibitory concentrations and epidemiological cut-off values—laboratory and clinical utility

[Gunnar Kahlmeter](#)^{1 2 3}, [John Turnidge](#)^{4 5}

Affiliations + expand

PMID: 38038445 PMCID: [PMC10732016](#) DOI: [10.1128/cmr.00100-22](#)

Free PMC article

MIC distributions and ECOFFs on EUCAST website

- >40 000 MIC distributions
- Up to 100 000 MIC-values per distribution
- Data from many investigators (1 – 100 per distrib.)
- Data from many time periods (1950 -)
- Data from many geographical areas and projects (USA, Europe, Australia, Far East, South America, Sentry, Mystic, etc)
- Data of multiple origin (Human clinical data, Surveillance programs, Pharma company development programmes, Veterinarian, Wild life, Food safety programs)
- EUCAST coined the expressions
 - "Wild type MIC distributions"
 - "Epidemiological cut-off values (ECOFF)".
- 25 000 hits per month
- Ownership: ESCMID and contributors

ECOFF is always the same irrespective of when (in time), where (geographical origin), and from whom (humans, animals) the organisms are obtained.

1. The usefulness of MIC wild type distributions and ECOFFs

- **A reference**
 - A wild-type distribution agreed by many investigators will serve as a reference of agent activity against a defined species.
- **A tool in the determination of clinical breakpoints**
 - When determining clinical breakpoints, the sequence of the discussion is: (a) identify what is “normal” (the wild type for the species and agent), (b) agree that the wild type is or is not a suitable target for treatment with the agent (if so, the wild type should be categorised S or I), c) discuss whether there is evidence to allow a higher breakpoint than the ECOFF. EUCAST requires that clinical breakpoints should not be set to split wild-type distributions
- **As a tool to exclude resistance.**
 - The ECOFF provides the most sensitive phenotypic measurement with which to identify and exclude resistance. This is of interest for resistance screening purposes and is often used by EUCAST. Next slide.

2. The usefulness of MIC wild type distributions and ECOFFs

- For surveillance of resistance development
 - Clinical breakpoints are in many ways unsuitable for determination and surveillance of resistance rates.
 - Not sensitive enough; resistance may go undetected
 - Change over time – clinical breakpoints are reviewed and revised at intervals
 - Differ between organisations
- For local, national, and international comparisons
 - Comparison of WT and NWT (via ECOFFs) is largely independent of origin of isolates (in time, geographically and the animal species), methods (as long as non-truncated MIC or disk diffusion) and of course clinical breakpoints.
- In lieu of clinical breakpoints
 - The wild type is not automatically susceptible; some wild type organisms are clinically resistant (*Enterococcus* spp vs. Aminoglycosides; *K.pneumoniae* vs. Ampicillin/amoxicillin).
 - If there is a well-founded clinical experience to successfully use a specific agent and dose for an infection with a specific organism, the ECOFF may be used in lieu of a clinical breakpoint.

3. The usefulness of MIC wild type distributions and ECOFFs

- In therapeutic drug monitoring

- in therapeutic drug monitoring and dosage adjustment in seriously ill patients, a practice is developing where drug exposure is compared to a measurement of the MIC of the infecting pathogen.

This is used to estimate whether the patient is receiving sufficient **exposure** (dosage) to ensure that PK-PD targets are reached.

Since a single MIC measurement cannot be relied upon (due to the intrinsic variation in assays), it is better to determine whether or not the isolate is WT or NWT for the agent in question, identify the ECOFF and to add one or two dilutions and to then aim for a PK-PD higher than this value.

This approach guarantees that assay variation has been accounted for, and ensures the highest margin for efficacy should dosage adjustment be required

